晚期宫颈癌-话题@MedSci

#晚期宫颈癌#

20篇内容 | 689人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1616421, encodeId=beee1616421ff, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=度伐利尤单抗治疗局部晚期宫颈癌III期研究，结果失败, objectType=article, longId=302279, objectId=6eee3022e979, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6eee3022e979, replyNumber=0, likeNumber=45, createdTime=2022-04-04, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6eee3022e979, moduleTitle=度伐利尤单抗治疗局部晚期宫颈癌III期研究，结果失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6eee3022e979)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616420, encodeId=61e11616420db, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=J Clin Oncol：信迪利单抗联合安罗替尼治疗PD-L1阳性晚期宫颈癌, objectType=article, longId=299549, objectId=91b029954956, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91b029954956, replyNumber=0, likeNumber=32, createdTime=2022-02-25, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91b029954956, moduleTitle=J Clin Oncol：信迪利单抗联合安罗替尼治疗PD-L1阳性晚期宫颈癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91b029954956)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616419, encodeId=560e161641903, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=Cancer：HIV-1蛋白酶抑制剂奈非那韦联合标准放化疗治疗局部晚期宫颈癌的效果, objectType=article, longId=293023, objectId=5fe32930236d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5fe32930236d, replyNumber=0, likeNumber=23, createdTime=2021-12-30, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5fe32930236d, moduleTitle=Cancer：HIV-1蛋白酶抑制剂奈非那韦联合标准放化疗治疗局部晚期宫颈癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5fe32930236d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616418, encodeId=93ef1616418d0, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=J Clin Oncol：PD-1和CTLA-4双重阻断二线治疗晚期宫颈癌疗效显著, objectType=article, longId=292558, objectId=2c632925589c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c632925589c, replyNumber=0, likeNumber=45, createdTime=2021-12-24, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c632925589c, moduleTitle=J Clin Oncol：PD-1和CTLA-4双重阻断二线治疗晚期宫颈癌疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c632925589c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616417, encodeId=b054161641e19, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=Gynecol Oncol：鳞状细胞癌抗原（SCC-Ag）是局部晚期宫颈癌患者的生存预后因素, objectType=article, longId=217443, objectId=bacd21e4438e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bacd21e4438e, replyNumber=0, likeNumber=31, createdTime=2021-09-24, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bacd21e4438e, moduleTitle=Gynecol Oncol：鳞状细胞癌抗原（SCC-Ag）是局部晚期宫颈癌患者的生存预后因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bacd21e4438e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616416, encodeId=14951616416fe, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=Cancer：HIV-1蛋白酶抑制剂奈非那韦联合标准放化疗治疗局部晚期宫颈癌的效果, objectType=article, longId=210992, objectId=3d082109924e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d082109924e, replyNumber=0, likeNumber=31, createdTime=2021-05-10, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d082109924e, moduleTitle=Cancer：HIV-1蛋白酶抑制剂奈非那韦联合标准放化疗治疗局部晚期宫颈癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d082109924e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616415, encodeId=2ff2161641517, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=J Clin Oncol：未来可期| 卡瑞利珠单抗联合阿帕替尼治疗晚期宫颈癌！, objectType=article, longId=202292, objectId=ae1420229214, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae1420229214, replyNumber=0, likeNumber=38, createdTime=2020-10-21, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae1420229214, moduleTitle=J Clin Oncol：未来可期| 卡瑞利珠单抗联合阿帕替尼治疗晚期宫颈癌！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae1420229214)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616414, encodeId=2142161641445, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=Agenus的PD-1单抗Balstilimab治疗晚期宫颈癌，获得FDA的快速通道指定, objectType=article, longId=191720, objectId=0445191e204e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0445191e204e, replyNumber=0, likeNumber=0, createdTime=2020-04-10, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0445191e204e, moduleTitle=Agenus的PD-1单抗Balstilimab治疗晚期宫颈癌，获得FDA的快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0445191e204e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616413, encodeId=011816164131a, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=Agenus的PD-1单抗Balstilimab联合CTLA-4单抗Zalifrelimab治疗晚期宫颈癌，获得FDA的快速通道指定, objectType=article, longId=190021, objectId=dadc19002166, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dadc19002166, replyNumber=0, likeNumber=27, createdTime=2020-03-16, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dadc19002166, moduleTitle=Agenus的PD-1单抗Balstilimab联合CTLA-4单抗Zalifrelimab治疗晚期宫颈癌，获得FDA的快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dadc19002166)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616412, encodeId=ee2a1616412e0, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=LN-145获FDA突破性疗法认定用于治疗化疗期间或之后进展的晚期宫颈癌, objectType=article, longId=166719, objectId=4a10166e19ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a10166e19ca, replyNumber=0, likeNumber=24, createdTime=2019-05-25, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a10166e19ca, moduleTitle=LN-145获FDA突破性疗法认定用于治疗化疗期间或之后进展的晚期宫颈癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a10166e19ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616411, encodeId=2f0b1616411d0, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=CLIN CANCER RES：骨骼肌损失可以作为局部晚期宫颈癌患者预后的标志, objectType=article, longId=152333, objectId=397315233363, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=397315233363, replyNumber=0, likeNumber=37, createdTime=2018-11-01, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=397315233363, moduleTitle=CLIN CANCER RES：骨骼肌损失可以作为局部晚期宫颈癌患者预后的标志, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=397315233363)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616410, encodeId=505816164108a, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=Lancet：贝伐单抗治疗晚期宫颈癌：GOG240研究最终分析报告, objectType=article, longId=117280, objectId=ed8511e28047, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed8511e28047, replyNumber=0, likeNumber=34, createdTime=2017-10-25, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed8511e28047, moduleTitle=Lancet：贝伐单抗治疗晚期宫颈癌：GOG240研究最终分析报告, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed8511e28047)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616409, encodeId=c1f6161640968, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=Lancet：GOG240 III期结果公布——贝伐单抗治疗晚期宫颈癌患者的OS&AE如何？, objectType=article, longId=107569, objectId=880d10e56917, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=880d10e56917, replyNumber=0, likeNumber=30, createdTime=2017-08-05, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=880d10e56917, moduleTitle=Lancet：GOG240 III期结果公布——贝伐单抗治疗晚期宫颈癌患者的OS&AE如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=880d10e56917)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616408, encodeId=9e4b16164085b, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=里程碑！欧盟批准罗氏安维汀（Avastin）联合化疗治疗晚期宫颈癌, objectType=article, longId=49147, objectId=a38a4914ee9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a38a4914ee9, replyNumber=0, likeNumber=38, createdTime=2015-04-10, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a38a4914ee9, moduleTitle=里程碑！欧盟批准罗氏安维汀（Avastin）联合化疗治疗晚期宫颈癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a38a4914ee9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616407, encodeId=5297161640e87, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=The Lancet Oncology：贝伐单抗有望用于治疗晚期宫颈癌, objectType=article, longId=46416, objectId=13de46416c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13de46416c3, replyNumber=0, likeNumber=43, createdTime=2015-02-01, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13de46416c3, moduleTitle=The Lancet Oncology：贝伐单抗有望用于治疗晚期宫颈癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13de46416c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616406, encodeId=f94216164066c, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=罗氏Avastin再获批 **用于晚期宫颈癌的生物药物, objectType=article, longId=43043, objectId=f21c43043db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f21c43043db, replyNumber=0, likeNumber=34, createdTime=2014-11-26, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f21c43043db, moduleTitle=罗氏Avastin再获批 **用于晚期宫颈癌的生物药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f21c43043db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616405, encodeId=354116164052a, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=JCO：提高晚期宫颈癌存活率的新疗法, objectType=article, longId=40836, objectId=87824083629, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87824083629, replyNumber=0, likeNumber=30, createdTime=2014-10-01, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87824083629, moduleTitle=JCO：提高晚期宫颈癌存活率的新疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87824083629)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616404, encodeId=ff011616404ae, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=FDA批准罗氏安维汀（Avastin）联合化疗治疗晚期宫颈癌, objectType=article, longId=39215, objectId=fcdb3921526, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcdb3921526, replyNumber=0, likeNumber=27, createdTime=2014-08-20, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcdb3921526, moduleTitle=FDA批准罗氏安维汀（Avastin）联合化疗治疗晚期宫颈癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcdb3921526)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616403, encodeId=cfb216164031a, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=JCO：培美曲塞联合顺铂治疗晚期宫颈癌安全有效, objectType=article, longId=38730, objectId=486438e3037, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=486438e3037, replyNumber=0, likeNumber=34, createdTime=2014-08-08, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=486438e3037, moduleTitle=JCO：培美曲塞联合顺铂治疗晚期宫颈癌安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=486438e3037)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616402, encodeId=db631616402f3, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=罗氏旗下阿瓦斯丁能延长晚期宫颈癌患者生存期, objectType=article, longId=19871, objectId=ab46198e1ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab46198e1ab, replyNumber=0, likeNumber=40, createdTime=2013-06-09, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab46198e1ab, moduleTitle=罗氏旗下阿瓦斯丁能延长晚期宫颈癌患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab46198e1ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

晚期宫颈癌

2020-05-29

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

度伐利尤单抗治疗局部晚期宫颈癌III期研究，结果失败

2022-04-04

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

J Clin Oncol：信迪利单抗联合安罗替尼治疗PD-L1阳性晚期宫颈癌

2022-02-25

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

Cancer：HIV-1蛋白酶抑制剂奈非那韦联合标准放化疗治疗局部晚期宫颈癌的效果

2021-12-30

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

J Clin Oncol：PD-1和CTLA-4双重阻断二线治疗晚期宫颈癌疗效显著

2021-12-24

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

Gynecol Oncol：鳞状细胞癌抗原（SCC-Ag）是局部晚期宫颈癌患者的生存预后因素

2021-09-24

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

Cancer：HIV-1蛋白酶抑制剂奈非那韦联合标准放化疗治疗局部晚期宫颈癌的效果

2021-05-10

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

J Clin Oncol：未来可期| 卡瑞利珠单抗联合阿帕替尼治疗晚期宫颈癌！

2020-10-21

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

Agenus的PD-1单抗Balstilimab治疗晚期宫颈癌，获得FDA的快速通道指定

2020-04-10

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

Agenus的PD-1单抗Balstilimab联合CTLA-4单抗Zalifrelimab治疗晚期宫颈癌，获得FDA的快速通道指定

2020-03-16

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

LN-145获FDA突破性疗法认定用于治疗化疗期间或之后进展的晚期宫颈癌

2019-05-25

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

CLIN CANCER RES：骨骼肌损失可以作为局部晚期宫颈癌患者预后的标志

2018-11-01

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

Lancet：贝伐单抗治疗晚期宫颈癌：GOG240研究最终分析报告

2017-10-25

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

Lancet：GOG240 III期结果公布——贝伐单抗治疗晚期宫颈癌患者的OS&AE如何？

2017-08-05

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

里程碑！欧盟批准罗氏安维汀（Avastin）联合化疗治疗晚期宫颈癌

2015-04-10

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

The Lancet Oncology：贝伐单抗有望用于治疗晚期宫颈癌

2015-02-01

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

罗氏Avastin再获批 **用于晚期宫颈癌的生物药物

2014-11-26

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

JCO：提高晚期宫颈癌存活率的新疗法

2014-10-01

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

FDA批准罗氏安维汀（Avastin）联合化疗治疗晚期宫颈癌

2014-08-20

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

JCO：培美曲塞联合顺铂治疗晚期宫颈癌安全有效

2014-08-08

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

罗氏旗下阿瓦斯丁能延长晚期宫颈癌患者生存期

2013-06-09

科室
- - 订阅+
  - 更多科室
工具
服务